Dapagliflozin
DAPA-HF, REWIND, other cardiometabolic science highlighted at CMHC
Top news of September: Losartan recalls, dapagliflozin in HF and more

Healio and Cardiology Today compiled a list of the most-viewed cardiology posts in September. This month, our readers were interested in recalls of losartan due to impurities, the DAPA-HF and DEFINE-HF studies showing benefit of dapagliflozin (Farxiga, AstraZeneca) in patients with HF regardless of diabetes status, the effect of a salt substitution regimen on hypertension and much more.
New drug trial results from EASD
Top stories in endocrinology: FDA OKs diabetes drug, fast tracks another for heart failure
Top stories in cardiology: Shaq discusses heart failure, and some without CVD could benefit from aspirin
DEFINE-HF: Dapagliflozin improves HF-related health regardless of diabetes status

PHILADELPHIA — In patients with HF with reduced ejection fraction with or without diabetes, the SGLT2 inhibitor dapagliflozin was associated with clinically meaningful improvements in HF-related health status or N-terminal pro-B type natriuretic peptide at 12 weeks, according to results of the DEFINE-HF trial presented at the Heart Failure Society of America Scientific Meeting.